Overview

An Open, Randomized, Multicentre, Phase II Pilot Study

Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate efficacy, safety and quality of life adjuvant docetaxel-cisplatin chemotherapy versus no adjuvant treatment in patients with completely resected NSCLC Stage I-II.
Phase:
Phase 2
Details
Lead Sponsor:
Central European Cooperative Oncology Group
Treatments:
Cisplatin
Docetaxel